Related references
Note: Only part of the references are listed.Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
William W. Busse et al.
LANCET RESPIRATORY MEDICINE (2019)
A Charter to Improve Patient Care in Severe Asthma
Andrew Menzies-Gow et al.
ADVANCES IN THERAPY (2018)
Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment
Stephanie Chen et al.
CURRENT MEDICAL RESEARCH AND OPINION (2018)
Appropriate use of oral corticosteroids for severe asthma
J. Michael Ramsahai et al.
MEDICAL JOURNAL OF AUSTRALIA (2018)
Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study
David B. Price et al.
JOURNAL OF ASTHMA AND ALLERGY (2018)
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma
Parameswaran Nair et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study
Akbar K. Waljee et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study
Akbar K. Waljee et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Eugene R. Bleecker et al.
LANCET (2016)
Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
J. Mark FitzGerald et al.
LANCET (2016)
Reductions in eosinophil biomarkers by benralizumab in patients with asthma
Tuyet-Hang Pham et al.
RESPIRATORY MEDICINE (2016)
MEDI-563, a humanized anti-IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
Roland Kolbeck et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Share Paper
